01. Doctor Overview
Dr. Rachel Sanborn received her medical degree in 1999 at the Oregon Health & Science University, then going on to complete an internal medicine residency at the University of Illinois College of Medicine and back to Oregon Health & Science for a fellowship in medical oncology and hematology.
Dr. Sanborn currently holds the position of Co-Director of the Providence Thoracic Oncology Program, where patients with thoracic malignancies like mesothelioma receive treatment. Dr. Sanborn maintains many active memberships to integrate the latest treatment methods and diagnostic tools into her approach, such as with the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
02. Fast Facts
Doctor Fast Facts
Main Specialty: Medical Oncology
Other Interests & Specialties: Cancer, chemotherapy, cancer during pregnancy, cancer genomics, cancer survivorship, chest wall tumors, EGFR mutation, endocrine complications of cancer therapy, esophageal cancer, lung cancer, lung masses, lung metastasis, malignant neoplasm of the esophagus, mediastinal tumor, mesothelioma, metastatic tumors to the lungs, non-small cell lung cancer, plasma cell dyscrasia, pulmonary metastasis, small cell lung cancer, teratogen exposure, thoracic malignancies, thymoma, thymus cancer, tracheal cancer, tracheal masses and unknown primary cancers.
Certifications, Awards & Accolades: American Society of Clinical Oncology member, International Association for the Study of Lung Cancer member, Free to Breathe member, Southwest Oncology Group Thoracic Working Group member, Hoosier Cancer Research Network Thoracic Clinical Trial Working Group member
Education & Experience:
- Residency for Internal Medicine at University of Illinois College of Medicine at Chicago
- Fellowship for Hematology/Oncology at Oregon Health & Science University
- Medical Degree from Oregon Health & Science University School of Medicine
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Oncology. March 2015;16(3):257-265. doi: 10.1016/S1470-2045(15)70054-9
Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma. Clinical Lung Cancer. July 2013;14(4):351-255. doi: 10.1016/j.cllc.2012.12.004